Chordate presents Ozilia at LSX World Congress on April 29-30

Chordate Medical is participating in this year's LSX World Congress in London on April 29-30. LSX World Congress is a leading event in the global life science sector, connecting innovative new solutions and start-up companies with major corporations and investors.

"LSX brings together potential investors in biotech, medtech, and healthtech from around the world in one place. It's a very fitting forum for us to present Ozilia as the latest development in migraine treatment," says Anders Weilandt, CEO of Chordate.

This year's edition of LSX World Congress is the tenth in its series. The purpose of the event is to connect capital with innovative developments to help create tomorrow's health solutions that can benefit more people.

"We already have the scientific evidence in place and are beginning to show proof of concept in several of our focus markets. The next step in the company's strategy is to find a buyer for the company. At LSX World Congress and other similar events we participate in during the spring, we find precisely the right target audience for us."

Read more about LSX World Congress

More press releases

We are a Swedish medical technology company listed on Nasdaq First North Growth Market.

Chordate has spent more than 10 years developing the Kinetic Oscillation Stimulation, K.O.S, a technique for treating rhinitis and migraine. We have a patent on K.O.S in the EU and the United States, as well as many other countries.

We have answered frequently asked questions in our FAQ. If you want to know more, please get in touch.

Please note that the MAR rules (Market Abuse Regulation) prohibits us from providing information to individual inquirers regarding matters of the company’s share, share price, economy and financials, commercial and scientific activities, and other information that potentially can alter the Market valuation of the traded share. We refer in general to the public information published by the company for such questions. Hence, emails with such questions will not be responded to individually.

IR contact